Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Growth Projections For The Idiopathic Pulmonary Fibrosis Market Size During 2025–2029?
The idiopathic pulmonary fibrosis market has demonstrated robust growth over recent years. Its valuation is expected to rise from $4.15 billion in 2024 to $4.37 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.2%. Historically, this expansion has been driven by an increasing aging population, limited treatment options, rising disease awareness, and ongoing healthcare infrastructure development.
The idiopathic pulmonary fibrosis market size is projected to undergo substantial expansion in the next few years. It is anticipated to reach $5.72 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.9%. This expansion during the forecast period can be ascribed to amplified research and development, the implementation of a precision medicine approach, a rise in disease incidence, progress in biomarker development, and governmental initiatives and funding. Noteworthy trends over the forecast horizon include improvements in diagnostic methods, the appearance of targeted therapies, widespread adoption of telemedicine and remote monitoring, the application of combination therapies, and advancements in lung transplantation.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12579&type=smp
Which Major Market Drivers Are Shaping The Future Of The Idiopathic Pulmonary Fibrosis Market?
The increasing occurrence of fibrotic disease is projected to fuel the expansion of the idiopathic pulmonary fibrosis market in the coming years. Fibrotic diseases, often termed fibrosis, encompass a range of medical conditions marked by an overabundance and buildup of fibrous connective tissue within different bodily organs or tissues. Medications for idiopathic pulmonary fibrosis aid in diminishing lung fibrosis and inflammation by acting on various signaling pathways linked to fibrosis. For example, data from December 2022, provided by the American Lung Association, a US-based lung association, indicated approximately 207,000 individuals were impacted in the United States, with about 58,000 new cases of idiopathic pulmonary fibrosis diagnosed annually; this condition is more prevalent in men than women and primarily affects those over 50 years of age. Consequently, the growing prevalence of fibrotic disease propels the idiopathic pulmonary fibrosis market.
How Is The Idiopathic Pulmonary Fibrosis Market Segmented?
The idiopathic pulmonary fibrosismarket covered in this report is segmented –
1) By Drug Type: Nintedanib; Pirfenidone; Other Drug Types
2) By Mode Of Action: Antifibrotic Agents; Tyrosine Kinase Inhibitors; Other Modes Of Action
3) By Route Of Administration: Oral; Parenteral
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Providers
5) By End Users: Hospitals And Clinics; Other End Users
Subsegments:
1) By Nintedanib: Indications; Dosage Forms; Administration Routes
2) By Pirfenidone: Indications; Dosage Forms; Administration Routes
3) By Other Drug Types: Specific Agents Or Classes; Emerging Therapies; Combination Therapies
What Trends Are Redefining The Idiopathic Pulmonary Fibrosis Market Dynamics?
Product innovation represents a significant trend gaining traction within the idiopathic pulmonary fibrosis market. Key companies active in the idiopathic pulmonary fibrosis market are dedicated to developing novel products to fortify their market position and achieve a competitive advantage. For example, in May 2022, Sandoz, a Switzerland-based firm specializing in generic and biosimilar medicines, released a generic version of pirfenidone. This product stands as the first AB-rated equivalent to Genentech’s Esbriet, intended for treating individuals diagnosed with idiopathic pulmonary fibrosis (IPF). This orally administered prescription drug is now obtainable by patients through specialty pharmacies, and those who qualify can utilize a USD 0 co-pay program.
Which Major Firms Are Strengthening Their Position In The Idiopathic Pulmonary Fibrosis Industry?
Major companies operating in the idiopathic pulmonary fibrosis market include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report
What Regional Growth Trends Are Shaping The Idiopathic Pulmonary Fibrosis Market Outlook?
North America was the largest region in the idiopathic pulmonary fibrosis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Idiopathic Pulmonary Fibrosis Market Report:
https://www.thebusinessresearchcompany.com/customise?id=12579&type=smp
Browse Through More Reports Similar to the Global Idiopathic Pulmonary Fibrosis Market 2025, By The Business Research Company
Pulmonary Arterial Hypertension Global Market Report 2025
Overactive Bladder Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/overactive-bladder-treatment-global-market-report
Constipation Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/constipation-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model